E
LABP

Ergoteles’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Ergoteles’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,290
Closed -$17K – 2163
2022
Q2 		$17K Buy
+2,290
New +$20.8K ﹤0.01% 1585

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

Ergoteles's LABP Position: Q3 2022 in Review

Ergoteles sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q3 2022, closing a stake of 2,290 shares — an estimated $17K sold.

Ergoteles first reported a position in LABP in Q2 2022 and held it in 1 quarter. The position peaked at $17K in Q2 2022. 31 funds tracked by Wall St. Rank hold LABP as of Q3 2022.

  • Ergoteles reported no remaining Landos Biopharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 2,290 Landos Biopharma, Inc. Common Stock shares in Q3 2022, an estimated $17K.
  • Ergoteles first reported a position in Landos Biopharma, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Ergoteles's Landos Biopharma, Inc. Common Stock position peaked at $17K in Q2 2022.
  • 31 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.